Novartis has received traditional approval from the US Food and Drug Administration (FDA) for Fabhalta® (iptacopan) to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.
Fabhalta is the first and only complement inhibitor approved for this indication and follows its accelerated approval in 2024 for reducing proteinuria in patients with primary IgAN. The approval was granted under the FDA’s priority review pathway - Read More.
Apple unveiled breakthrough sleep and hearing health features coming to the Apple Watch and AirPods Pro 2 that further deliver on Apple’s commitment to health with experi...
Flexible coils for magnetic resonance imaging are being designed to search for breast cancer faster and with less disadvantages. In a project funded by the Austrian Scien...
Pfizer introduced PfizerForAll, a user-friendly digital platform designed to make access to healthcare and managing health and wellness more seamless for people across th...
From the high tech to the medical sector, AI is showing all its resources, opening the doors to many global innovations. In a rapidly changing world, modern society is...
Stryker announced the launch of LIFEPAK 35 monitor/defibrillator, the latest product in the monitor/defibrillator space, offering advanced technology and built on an intu...
Henry Schein UK announced today the expansion of the company’s CRITERION® brand, which includes gloves as well as soon a head-to-toe line of personal protective equipment...
Basel- April 2024- Roche announced that the U.S. Food and Drug Administration (FDA) has approved Alecensa® (alectinib) for adjuvant treatment following tumour resection f...
Basel, Switzerland- Roche is one step closer to gaining FDA approval for Xolair® (omalizumab). The agency accepts its supplemental Biologics License Application (sBLA) un...
A virtual marketplace leading your business into the future
